Art. -Nr.: HY-D0973

EGTA-AM

(Synonyms: EGTA Acetoxymethyl ester)

10 Cited Publications

Kundenbewertung

Based on 10 publication(s) in Google Scholar

EGTA-AM is a membrane permeable form of EGTA, can be passively loaded into cells to generate intracellular EGTA; EGTA-AM is also a Ca²⁺ chelator with slow chelating dynamics.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.81%
CAS. Nr.: 99590-86-0
Formel: C₂₆H₄₀N₂O₁₈
Molecular Weight:668.60

Speicherung:

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

EGTA-AM Chemical Structure

CAS. Nr.: 99590-86-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
Chemical Information
Publications (10)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

EGTA-AM is a membrane permeable form of EGTA, can be passively loaded into cells to generate intracellular EGTA; EGTA-AM is also a Ca²⁺ chelator with slow chelating dynamics.

In Vitro

EGTA-AM (50 μM) markedly reduces the asynchronous excitatory postsynaptic currents (aEPSC) to 58.9 ± 8.1% of the control level, but only reduces the synchronous excitatory postsynaptic currents (EPSCs), measured as charge transfer produced by the stimulation train^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 99590-86-0
Appearance Liquid (Density: 1.303 g/cm³)
Molecular Weight 668.60
Formel C₂₆H₄₀N₂O₁₈
Color Colorless to light yellow
SMILES

O=C(OCOC(C)=O)CN(CC(OCOC(C)=O)=O)CCOCCOCCN(CC(OCOC(C)=O)=O)CC(OCOC(C)=O)=O
Synonyms

EGTA Acetoxymethyl ester
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (10)

All Cell Proliferation/Viability AssayWBIFIP

Sort by:

Journal Impact Factor

Nat Commun

LPA signaling acts as a cell-extrinsic mechanism to initiate cilia disassembly and promote neurogenesis. [Abstract]

2021 Jan 28;12(1):662. PMID: 33510165

EGTA-AM purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Jan 28;12(1):662. [Abstract]

CMZ or EGTA blocks serum- and LPA- induced Aurora A activation. Ciliated RPE-1 cells were pretreated with CMZ (5 μM), EGTA (0.5 mM) or DMSO control for 30 min, and then cells were stimulated with 10% FBS or 2 μM LPA for 2 h. Cells were stained with anti-p-AurA (Aurora A, green), anti-Ac-tub (Ac-tubulin, red) antibodies. Scale bar: 5 μm (main image) and 1 μm (magnified region).

EGTA-AM purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Jan 28;12(1):662. [Abstract]

CMZ or EGTA blocks serum- and LPA- induced cilia disassembly. Ciliated RPE-1 cells were pretreated with Ki16425 (40 μM), CMZ (5 μM), EGTA (0.5 mM) or DMSO control for 30 min, and then cells were stimulated with 10% FBS or 2 μM LPA for 2 h.
Exp Mol Med

Piezo1 activation in endothelial cells aggravates microvascular ischemia-reperfusion injury in limbs by enhancing ferroptosis. [Abstract]

2026 Feb;58(1):143-160. PMID: 41507309
Adv Sci (Weinh)

Inhibition of Calcium-Dependent Lipid Droplets Relocation of ACSL4-PKCβ-ALOX15 Complex Alleviates Ferroptosis and Acute Pancreatitis. [Abstract]

2026 Apr;13(19):e15768. PMID: 41589658

EGTA-AM purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2026 Apr;13(19):e15768. [Abstract]

Calcium chelators treatment blocked ferroptosis and lipid peroxidation. HT1080 cells were treated with RSL3 (1 µM, for 10 h), erastin (10 µM, for 20 h) or cystine starvation (for 30 h) with or without calcium chelators, then cell death and lipid ROS were measured. EDTA‐AM (40 µM), EGTA‐AM (50 µM), BHQ (50 µM).

EGTA-AM purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2026 Apr;13(19):e15768. [Abstract]

L‐type calcium channel blockers or calcium chelators treatment suppress erastin (10 µM, for 8 h) or RSL3 (1 µM, for 6 h) induced phosphorylation of cPKC without changing their protein level. HT1080 cells were treated with indicated compounds. Western blot images confirmed the expression of the indicated proteins. Erastin (10 µM), Beni: Benidipine (50 µM) Xini: Xinidipine (20 µM), EGTA‐AM (50 µM), BHQ (50 µM).

EGTA-AM purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2026 Apr;13(19):e15768. [Abstract]

EGTA‐AM (50 µM for 8 h) does not affect the formation of ACSL4‐PKCβ‐ALOX15 complex. The IP assay was performed using an antibody against HA tag using indicated cell lysate. Western blot images confirmed the expression of the indicated proteins.

EGTA-AM purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2026 Apr;13(19):e15768. [Abstract]

EGTA treatment blocked the effect of the erastin on the formation of ACSL4‐PKCβ‐ALOX15 complex. The IP assay was performed using an antibody against FLAG tag using indicated cell lysate. Western blot images confirmed the expression of the indicated proteins in MDA‐MB‐231 cells. erastin (20 µM for 8 h), EGTA (50 µM for 8 h).
Dev Cell

Using an ER-specific optogenetic mechanostimulator to understand the mechanosensitivity of the endoplasmic reticulum. [Abstract]

2024 Apr 1:S1534-5807(24)00180-1. PMID: 38569547
Cell Rep

circATF6 triggers calcium overload to synergize with EGFR-TKI in non-small cell lung cancer via modulation of proteostasis. [Abstract]

2025 Dec 5;44(12):116659. PMID: 41351835
Eur J Pharmacol

Isoliensinine promotes vasorelaxation and inhibits constriction by regulating the calcium channel in hypertension: In vitro and in vivo approaches. [Abstract]

2025 May 23:177765. PMID: 40414594
PLoS Pathog

Newcastle disease virus infection induces parthanatos in tumor cells via calcium waves. [Abstract]

2024 Dec 2;20(12):e1012737. PMID: 39621796
Front Physiol

Endoplasmic Reticulum Stress/Ca2+-Calmodulin-Dependent Protein Kinase/Signal Transducer and Activator of Transcription 3 Pathway Plays a Role in the Regulation of Cellular Zinc Deficiency in Myocardial Ischemia/Reperfusion Injury. [Abstract]

2022 Jan 5:12:736920. PMID: 35069232
Res Sq

2026 Mar 11.
Research Square Preprint

2024 Mar 13.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (149.57 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.4957 mL

7.4783 mL

14.9566 mL

5 mM

0.2991 mL

1.4957 mL

2.9913 mL

10 mM

0.1496 mL

0.7478 mL

1.4957 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (3.74 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (3.74 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.74 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (270 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Li MJ, et al. Cholinergic and glutamatergic transmission at synapses between pedunculopotine tegmental nucleus axonal terminals and A7 catecholamine cell group noradrenergic neurons in the rat. Neuropharmacology. 2016 Nov;110(Pt A):237-50 [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.4957 mL	7.4783 mL	14.9566 mL	37.3916 mL
	5 mM	0.2991 mL	1.4957 mL	2.9913 mL	7.4783 mL
	10 mM	0.1496 mL	0.7478 mL	1.4957 mL	3.7392 mL
	15 mM	0.0997 mL	0.4986 mL	0.9971 mL	2.4928 mL
	20 mM	0.0748 mL	0.3739 mL	0.7478 mL	1.8696 mL
	25 mM	0.0598 mL	0.2991 mL	0.5983 mL	1.4957 mL
	30 mM	0.0499 mL	0.2493 mL	0.4986 mL	1.2464 mL
	40 mM	0.0374 mL	0.1870 mL	0.3739 mL	0.9348 mL
	50 mM	0.0299 mL	0.1496 mL	0.2991 mL	0.7478 mL
	60 mM	0.0249 mL	0.1246 mL	0.2493 mL	0.6232 mL
	80 mM	0.0187 mL	0.0935 mL	0.1870 mL	0.4674 mL
	100 mM	0.0150 mL	0.0748 mL	0.1496 mL	0.3739 mL

Keywords

EGTA-AM

10 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

EGTA-AM

Publications Citing Use of MedChemExpress (MCE) EGTA-AM

Biologische Aktivität

Chemical Information

Publications (10)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

EGTA-AM Related Classifications

HY-D0973 Related Classifications